127 related articles for article (PubMed ID: 17923463)
21. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Anand IS; Latini R; Florea VG; Kuskowski MA; Rector T; Masson S; Signorini S; Mocarelli P; Hester A; Glazer R; Cohn JN;
Circulation; 2005 Sep; 112(10):1428-34. PubMed ID: 16129801
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Lazzari P; Fogari E; Mugellini A; Preti P
Hypertens Res; 2005 Mar; 28(3):209-14. PubMed ID: 16097363
[TBL] [Abstract][Full Text] [Related]
23. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
[TBL] [Abstract][Full Text] [Related]
24. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
Xie QY; Wang YJ; Sun ZL; Yang TL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
[TBL] [Abstract][Full Text] [Related]
25. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
Serebruany VL; Pokov AN; Malinin AI; O'Connor C; Bhatt DL; Tanguay JF; Sane DC; Hennekens CH
Am Heart J; 2006 Jan; 151(1):92-9. PubMed ID: 16368298
[TBL] [Abstract][Full Text] [Related]
26. Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: relation to insulin resistance.
Tso TK; Huang WN
J Rheumatol; 2007 Apr; 34(4):726-30. PubMed ID: 17309130
[TBL] [Abstract][Full Text] [Related]
27. Markers of endothelial dysfunction in hyperglycaemic Asian Indian subjects.
Viswanathan V; Snehalatha C; Nair MB; Ramachandran A
J Diabetes Complications; 2004; 18(1):47-52. PubMed ID: 15019600
[TBL] [Abstract][Full Text] [Related]
28. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
[TBL] [Abstract][Full Text] [Related]
29. Pulse pressure responses in patients treated with Valsartan and hydrochlorothiazide combination therapy.
Carretta R; Trenkwalder P; Martinez F; Tykarski A; Teitelbaum I; Fagan T; Oddou P; Mallion J
J Int Med Res; 2003; 31(5):370-7. PubMed ID: 14587303
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy.
Dejica D; Grigorescu M; Dejica V; Radu C; Neculoiu D
Rom J Gastroenterol; 2002 Dec; 11(4):277-83. PubMed ID: 12532197
[TBL] [Abstract][Full Text] [Related]
31. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
Conran N; Fattori A; Saad ST; Costa FF
Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
[TBL] [Abstract][Full Text] [Related]
32. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
Hemelaar M; Kenemans P; Schalkwijk CG; Braat DD; van der Mooren MJ
Hum Reprod; 2006 Jun; 21(6):1635-42. PubMed ID: 16501036
[TBL] [Abstract][Full Text] [Related]
33. [Effects of angiotensin II on inflammation mediators in healthy subjects].
Lottermoser K; Ulrich-Merzenich G; Vetter H; Düsing R
Dtsch Med Wochenschr; 2003 Nov; 128(47):2470-5. PubMed ID: 14628252
[TBL] [Abstract][Full Text] [Related]
34. [Dynamic changes of cytokines in G-CSF mobilized peripheral blood].
Li CX; Wu DP; Chang WR; Zhu HT; Cen JN; Zhang XG
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):398-401. PubMed ID: 14642174
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of valsartan in patients with mild to moderate essential hypertension.
Nouh MS; Halim SA
Saudi Med J; 2002 May; 23(5):521-5. PubMed ID: 12070572
[TBL] [Abstract][Full Text] [Related]
36. Valsartan/hydrochlorothiazide.
Langtry HD; McClellan KJ
Drugs; 1999 May; 57(5):751-5; discussion 756-8. PubMed ID: 10353300
[TBL] [Abstract][Full Text] [Related]
37. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events.
Blann AD; Seigneur M; Steiner M; Miller JP; McCollum CN
Thromb Haemost; 1998 Jun; 79(6):1080-5. PubMed ID: 9657427
[TBL] [Abstract][Full Text] [Related]
38. Valsartan and retinal endothelial function in elderly hypertensive patients.
Oehmer S; Harazny J; Delles C; Schwarz T; Handrock R; Michelson G; Schmieder RE
Blood Press; 2006; 15(3):185-91. PubMed ID: 16864162
[TBL] [Abstract][Full Text] [Related]
39. Levels of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in children with Henoch-Schönlein purpura.
Wang LJ; Yang YH; Lin YT; Chiang BL
J Microbiol Immunol Infect; 2006 Apr; 39(2):109-13. PubMed ID: 16604242
[TBL] [Abstract][Full Text] [Related]
40. Additional benefits of RAS blockade in the treatment of black hypertensives using valsartan/hydrochlorothiazide combination.
Cardiovasc J S Afr; 2005; 16(5):285. PubMed ID: 16307164
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
